GC Therapeutics (GCTx), a pioneering biotechnology company advancing groundbreaking iPSC-based cell therapies, today announced the appointment of two industry leaders to its executive team. Kai-Hsin Chang, Ph.D., is a former drug development leader at Editas, and will serve as Head of Drug Development, SVP and Azadeh Golipour, Ph.D., is a tech ops veteran previously at AVROBIO joining as Head of Technical Operations, SVP.
Dr. Chang brings a wealth of expertise in drug development, regulatory strategy, and translational medicine from her tenure at Editas Medicine, where she played a key role in advancing genome-editing therapies through critical preclinical and clinical stages with multiple successful INDs. Her extensive background will significantly strengthen GC Therapeutics’ strategic and operational capabilities in drug development, accelerating the company’s journey toward delivering life-changing treatments.
"I am excited to join GC Therapeutics at such a transformative stage," said Dr. Chang. "GCTx’s cutting-edge approach, particularly its innovative TFome™ platform, offers a remarkable opportunity to bring impactful therapies to patients. I am thrilled to contribute to a forward-thinking team that is not only setting new standards in cell therapy but also striving to make a profound difference in patients’ lives.”
Dr. Golipour brings extensive experience in the manufacturing and scaling of gene and cell therapies, having successfully advanced multiple products from early-stage discovery through clinical manufacturing. Her leadership in technical operations at AVROBIO was instrumental in building robust, scalable manufacturing platforms critical to therapeutic commercialization. At GC Therapeutics, she will harness her expertise to drive innovative manufacturing solutions, propelling the company’s vision to bring their revolutionary technology to life.
"GC Therapeutics stands at the forefront of innovation, bridging cutting-edge science with clinical translation," said Dr. Golipour. "With its bold vision and highly differentiated technology, GC Therapeutics has a unique opportunity to transform the future of cell therapy by enabling the rapid, efficient, and scalable manufacturing of off-the-shelf allogeneic cell therapies. I am excited to collaborate with this pioneering team to drive technological advancements and deliver the next generation of cell therapies to patients."
“Azadeh and Kai-Hsin are outstanding leaders whose expertise in cell and gene therapy development will be instrumental in shaping the future of medicine,” said Parastoo Khoshakhlagh, Ph.D., CEO and co-founder of GC Therapeutics. “Their leadership will help accelerate our mission to develop the next generation of cell therapies - treatments that are not only groundbreaking but also accessible to all patients who need them. With their expertise, we are driving a new era of innovation to transform patient care.”
About GC Therapeutics
GC Therapeutics (GCTx) is a biopharmaceutical company created to scale and unlock the next generation of cell therapy-based medicines. GCTx’s induced pluripotent stem cell (iPSC) programming platform, TFome™ (tee-eff-ome), integrates the latest advancements in synthetic biology, gene editing, cell engineering and machine learning to overcome the therapeutic development and scaling complexities associated with cell therapy and improve patient access across a broad range of disease areas. GCTx’s initial focus is on developing first-in-class and best-in-class cell therapies for gastrointestinal, neurological and immunological diseases. Founded in 2019, GCTx is based in Cambridge, MA and has raised $75 million to date from leading life sciences investors. For more information, please visit us at www.gc-tx.com and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250415582849/en/
Contacts
Vivian Zou
vivian.zou@gc-tx.com
